Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -3.96% | 58.19 | 0.0% | $1899.37m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.26% | 597.00 | 2.5% | $1174.48m | |
| GILD | Gilead Sciences, Inc. | -1.02% | 76.75 | 1.0% | $975.82m | |
| AMGN | Amgen, Inc. | 2.17% | 225.67 | 1.3% | $660.44m | |
| NVAX | Novavax, Inc. | 3.67% | 46.30 | 102.0% | $655.72m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -2.61% | 265.69 | 1.9% | $544.78m | |
| ILMN | Illumina, Inc. | -1.20% | 354.11 | 3.5% | $388.06m | |
| BIIB | Biogen, Inc. | 2.36% | 306.72 | 1.6% | $378.26m | |
| SRNE | Sorrento Therapeutics, Inc. | 6.74% | 4.12 | 1.8% | $269.11m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.35% | 115.21 | 2.0% | $241.70m | |
| SGEN | Seattle Genetics, Inc. | -1.36% | 148.39 | 6.1% | $223.95m | |
| A | Agilent Technologies, Inc. | -0.83% | 90.38 | 1.6% | $215.81m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.59% | 105.80 | 4.3% | $184.97m | |
| SRPT | Sarepta Therapeutics, Inc. | 2.06% | 147.99 | 13.9% | $156.63m | |
| INCY | Incyte Corp. | -0.31% | 93.51 | 2.5% | $153.41m |
Company Profile
Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.